Bank of New York Mellon Corp Reduces Stock Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Bank of New York Mellon Corp reduced its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 3.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,468,609 shares of the biotechnology company's stock after selling 52,557 shares during the period. Bank of New York Mellon Corp owned about 0.62% of ADMA Biologics worth $29,137,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ADMA. PNC Financial Services Group Inc. boosted its holdings in shares of ADMA Biologics by 13.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 18,772 shares of the biotechnology company's stock valued at $322,000 after acquiring an additional 2,279 shares during the last quarter. AlphaQuest LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at $84,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of ADMA Biologics by 7.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,960 shares of the biotechnology company's stock valued at $1,131,000 after acquiring an additional 4,586 shares during the last quarter. HighTower Advisors LLC boosted its holdings in shares of ADMA Biologics by 13.6% in the 4th quarter. HighTower Advisors LLC now owns 99,381 shares of the biotechnology company's stock valued at $1,704,000 after acquiring an additional 11,910 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of ADMA Biologics by 6.6% in the 4th quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock valued at $7,862,000 after purchasing an additional 28,500 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ADMA. Raymond James Financial boosted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

ADMA Biologics Price Performance

NASDAQ:ADMA traded down $0.86 during trading hours on Friday, reaching $16.73. 3,829,943 shares of the company were exchanged, compared to its average volume of 3,656,563. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The stock's 50-day moving average is $19.29 and its 200-day moving average is $18.76. The firm has a market cap of $3.99 billion, a PE ratio of 19.68 and a beta of 0.43. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business's revenue was up 40.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.08 earnings per share. On average, sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock worth $9,644,269 over the last three months. Insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.